Skip to main
BEAT

HeartBeam (BEAT) Stock Forecast & Price Target

HeartBeam (BEAT) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartBeam is positioned at the intersection of evolving trends in remote patient monitoring, digital cardiology, and decentralized healthcare delivery. This positions the company for significant revenue potential in the growing cardiovascular disease market. With FDA clearance for its ECG solutions and a focus on concierge and specialty medicine practices, HeartBeam has a strategic advantage in capturing a high-touch market segment and establishing recurring revenue prior to broader deployment.

Bears say

HeartBeam is a medical technology company with a negative outlook due to several fundamental reasons. The company's commercial strategy relies on a capital-efficient sales model and enrollment of entire physician practices, which may pose high adoption and competitive risks. Additionally, the company's proposed on-demand 12-lead ECG patch and expansion into the broader cardiology market may face significant regulatory, clinical, and market development hurdles. The company's reliance on additional capital for commercialization and potential dilution also raises concerns about its long-term financial stability.

HeartBeam (BEAT) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HeartBeam (BEAT) Forecast

Analysts have given HeartBeam (BEAT) a Strong Buy based on their latest research and market trends.

According to 4 analysts, HeartBeam (BEAT) has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HeartBeam (BEAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.